Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2020 Filed Feb 6, 2020 19:54 UTC |
Parham Richelle PDirector
|
GrantRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003963 · form4.xml · derivative · entry 1 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213 Underlying: Common Stock · 986 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:50 UTC |
Gilliland Dwight GaryDirector
|
GrantRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003959 · form4.xml · derivative · entry 1 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213 Underlying: Common Stock · 986 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:49 UTC |
Davis Jeffrey A.Director
|
GrantRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003958 · form4.xml · derivative · entry 1 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,159 Underlying: Common Stock · 986 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:48 UTC |
BELINGARD JEAN-LUCDirector
|
GrantRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003957 · form4.xml · derivative · entry 1 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213 Underlying: Common Stock · 986 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:46 UTC |
ANDERSON KERRII BDirector
|
GrantRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003956 · form4.xml · derivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213 Underlying: Common Stock · 986 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:34 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
GrantNon-qualified Stock Options · Derivative | 3,600 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-003951 · form4.xml · derivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires 2030-02-03 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:34 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
GrantRestricted Stock Unit · Derivative | 840 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003951 · form4.xml · derivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,637 Underlying: Common Stock · 840 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:33 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
GrantNon-qualified Stock Options · Derivative | 7,300 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-003950 · form4.xml · derivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,300 Underlying: Common Stock · 7,300 shares Expires 2030-02-03 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:33 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
GrantRestricted Stock Unit · Derivative | 1,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003950 · form4.xml · derivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,534 Underlying: Common Stock · 1,680 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:32 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
GrantNon-qualified Stock Options · Derivative | 7,300 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-003949 · form4.xml · derivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,300 Underlying: Common Stock · 7,300 shares Expires 2030-02-03 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:32 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
GrantRestricted Stock Unit · Derivative | 1,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003949 · form4.xml · derivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,324 Underlying: Common Stock · 1,680 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:29 UTC |
Caveney Brian JEVP, President of Diagnostics
|
GrantNon-qualified Stock Options · Derivative | 7,300 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-003946 · form4.xml · derivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,300 Underlying: Common Stock · 7,300 shares Expires 2030-02-03 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:29 UTC |
Caveney Brian JEVP, President of Diagnostics
|
GrantRestricted Stock Unit · Derivative | 1,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003946 · form4.xml · derivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,057 Underlying: Common Stock · 1,680 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:30 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantNon-qualified Stock Options · Derivative | 12,600 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-003948 · form4.xml · derivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,600 Underlying: Common Stock · 12,600 shares Expires 2030-02-03 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:30 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantRestricted Stock Unit · Derivative | 2,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003948 · form4.xml · derivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,364 Underlying: Common Stock · 2,910 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person, including the Restricted Stock Units reported in this row. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:27 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantNon-qualified Stock Options · Derivative | 1,900 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-003945 · form4.xml · derivative · entry 2 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Underlying: Common Stock · 1,900 shares Expires 2030-02-03 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:27 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantRestricted Stock Unit · Derivative | 450 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003945 · form4.xml · derivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,050 Underlying: Common Stock · 450 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:21 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
GrantNon-qualified Stock Options · Derivative | 4,900 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-003944 · form4.xml · derivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 Underlying: Common Stock · 4,900 shares Expires 2030-02-03 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:21 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
GrantRestricted Stock Unit · Derivative | 1,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003944 · form4.xml · derivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,004 Underlying: Common Stock · 1,120 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 7, 2020 20:38 UTC |
Kong GarhengDirector
|
GrantRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004311 · form4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213 Underlying: Common Stock · 986 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 7, 2020 23:20 UTC Amendment |
van der Vaart Sandra DSVP, Global General Counsel
|
GrantNon-qualified Stock Options · Derivative | 3,900 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-004425 · form4a.xml · derivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,900 Underlying: Common Stock · 3,900 shares Expires 2030-02-03 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · kind: This amended form is filed to update the number of Employee Stock Options and Restricted Stock Units awarded and set for on Table II. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 7, 2020 23:20 UTC Amendment |
van der Vaart Sandra DSVP, Global General Counsel
|
GrantRestricted Stock Unit · Derivative | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004425 · form4a.xml · derivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,697 Underlying: Common Stock · 900 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · kind: This amended form is filed to update the number of Employee Stock Options and Restricted Stock Units awarded and set for on Table II. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 16:21 UTC |
KING DAVID PDirector
|
GrantRestricted Stock Unit · Derivative | 38,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-000356 · form4.xml · derivative · entry 1 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,527 Underlying: Common Stock · 38,570 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest on 1/1/2021. F2 · derivative.expiration_date: The Restricted Stock Units vest on 1/1/2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:07 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-034411 · form4.xml · derivative · entry 3 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227 Underlying: Common Stock · 3,271 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · shares: Reflects a reduction by 8 Restricted Stock Units that were inadvertently included on the reporting person's original Form 4 filed on December 7, 2018 due to a calculation error. F3 · derivative.exercise_date: The Restricted Stock Units vested fully on December 4, 2019. F3 · derivative.expiration_date: The Restricted Stock Units vested fully on December 4, 2019. F2 · derivative.underlying_shares: Reflects a reduction by 8 Restricted Stock Units that were inadvertently included on the reporting person's original Form 4 filed on December 7, 2018 due to a calculation error. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:07 UTC |
BELINGARD JEAN-LUCDirector
|
Tax withholdingCommon Stock | 327 | $171.82 | $56,185.14 |
DisclosureSEC source: 0001127602-19-034411 · form4.xml · nonDerivative · entry 2 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,957 Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:07 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionCommon Stock | 3,271 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-034411 · form4.xml · nonDerivative · entry 1 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| December 01, 2019 Filed Dec 4, 2019 21:01 UTC |
Davis Jeffrey A.Director
|
GrantRestricted Stock Unit · Derivative | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-034224 · form4.xml · derivative · entry 1 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173 Underlying: Common Stock · 173 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on 12/1/2020. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on 12/1/2020. Read SEC document |
| November 05, 2019 Filed Nov 8, 2019 00:56 UTC |
Caveney Brian JEVP, President of Diagnostics
|
GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-032263 · form4.xml · derivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,377 Underlying: Common Stock · 6,030 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 11/5/2020. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 11/5/2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 05, 2019 Filed Nov 8, 2019 00:53 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-032260 · form4.xml · derivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,644 Underlying: Common Stock · 6,030 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 11/5/2020. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 11/5/2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:14 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
GrantRestricted Stock Unit · Derivative | 6,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031973 · form4.xml · derivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,854 Underlying: Common Stock · 6,020 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 11/1/2020. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 11/1/2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:08 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantRestricted Stock Unit · Derivative | 30,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031970 · form4.xml · derivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,454 Underlying: Common Stock · 30,080 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units will vest in three installments as follows: 30% of the Restricted Stock Units will vest on November 1, 2020; 30% of the Restricted Stock Units will vest on November 1, 2021; and 40% of the Restricted Stock Units will vest on November 1, 2022, with the third installment subject to a relative total shareholder return ("TSR") modifier that may adjust the third installment of the Restricted Stock Units upward or downward 25% based on our three-year cumulative relative TSR. F2 · derivative.expiration_date: The Restricted Stock Units will vest in three installments as follows: 30% of the Restricted Stock Units will vest on November 1, 2020; 30% of the Restricted Stock Units will vest on November 1, 2021; and 40% of the Restricted Stock Units will vest on November 1, 2022, with the third installment subject to a relative total shareholder return ("TSR") modifier that may adjust the third installment of the Restricted Stock Units upward or downward 25% based on our three-year cumulative relative TSR. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:04 UTC |
Schechter Adam HDirector · President & CEO
|
GrantNon-qualified Stock Options · Derivative | 65,100 | $0.00 Strike: $191.51 | $0.00 |
DisclosureSEC source: 0001127602-19-031969 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,100 Underlying: Common Stock · 65,100 shares Expires 2029-10-31 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:04 UTC |
Schechter Adam HDirector · President & CEO
|
GrantNon-qualified Stock Options · Derivative | 24,800 | $0.00 Strike: $166.53 | $0.00 |
DisclosureSEC source: 0001127602-19-031969 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,800 Underlying: Common Stock · 24,800 shares Expires 2029-10-31 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:04 UTC |
Schechter Adam HDirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 6,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031969 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,247 Underlying: Common Stock · 6,020 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 11/1/2020. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 11/1/2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 21:25 UTC |
KING DAVID PDirector · President & CEO
|
SaleCommon Stock | 12,352 | $166.21 | $2,053,053.09 |
DisclosureSEC source: 0001127602-19-031280 · form4.xml · nonDerivative · entry 3 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,933.3942 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · price: The price of $166.2122 per share represents a weighted average of sales prices ranging from $165.79 to $166.48 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F3 · balance_after: Amount includes 168.7938 shares acquired on June 28, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Amount also includes 38,555 shares transferred by the reporting person's grantor retained annuity trust to the reporting person.. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 21:25 UTC |
KING DAVID PDirector · President & CEO
|
SaleCommon Stock | 10,391 | $165.32 | $1,717,831.81 |
DisclosureSEC source: 0001127602-19-031280 · form4.xml · nonDerivative · entry 2 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,285.3942 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: The price of $165.3192 per share represents a weighted average of sales prices ranging from $164.79 to $165.77 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F3 · balance_after: Amount includes 168.7938 shares acquired on June 28, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Amount also includes 38,555 shares transferred by the reporting person's grantor retained annuity trust to the reporting person.. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 21:25 UTC |
KING DAVID PDirector · President & CEO
|
SaleCommon Stock | 7,434 | $164.16 | $1,220,331.99 |
DisclosureSEC source: 0001127602-19-031280 · form4.xml · nonDerivative · entry 1 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,676.3942 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price of $164.1555 per share represents a weighted average of sales prices ranging from $163.69 to $164.68 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F3 · balance_after: Amount includes 168.7938 shares acquired on June 28, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Amount also includes 38,555 shares transferred by the reporting person's grantor retained annuity trust to the reporting person.. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 17:40 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionNon-qualified Stock Options · Derivative | 2,600 | $0.00 Strike: $98.49 | $0.00 |
DisclosureSEC source: 0001127602-19-029077 · form4.xml · derivative · entry 4 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Director stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2008 Stock Incentive Plan. F4 · derivative.exercise_date: The options vested in three equal annual installments beginning on the date reflected in this column and are now fully exercisable. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 17:40 UTC |
ANDERSON KERRII BDirector
|
SaleCommon Stock | 2,600 | $171.85 | $446,810.00 |
DisclosureSEC source: 0001127602-19-029077 · form4.xml · nonDerivative · entry 2 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,933 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 17:40 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionCommon Stock | 2,600 | $98.49 | $256,074.00 |
DisclosureSEC source: 0001127602-19-029077 · form4.xml · nonDerivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: On August 27, 2019, the reporting person contributed 1,200 shares of common stock to a grantor retained annuity trust for the benefit of certain of her family members and for which the reporting person is the annuitant. The reporting person is the trustee of the trust. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 13:54 UTC |
Uthgenannt Lisa JChief Human Resources Officer
|
Exercise / conversionNon-qualified Stock Options · Derivative | 2,466 | $0.00 Strike: $130.60 | $0.00 |
DisclosureSEC source: 0001127602-19-028025 · form4.xml · derivative · entry 3 Uthgenannt Lisa J · CIK 0001636456 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,234 Underlying: Common Stock · 2,466 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F3 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 13:54 UTC |
Uthgenannt Lisa JChief Human Resources Officer
|
SaleCommon Stock | 2,466 | $168.59 | $415,742.94 |
DisclosureSEC source: 0001127602-19-028025 · form4.xml · nonDerivative · entry 2 Uthgenannt Lisa J · CIK 0001636456 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,659.9747 F1 · balance_after: Amount includes 21.8965 shares acquired on June 28, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 13:54 UTC |
Uthgenannt Lisa JChief Human Resources Officer
|
Exercise / conversionCommon Stock | 2,466 | $130.60 | $322,059.60 |
DisclosureSEC source: 0001127602-19-028025 · form4.xml · nonDerivative · entry 1 Uthgenannt Lisa J · CIK 0001636456 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125.9747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount includes 21.8965 shares acquired on June 28, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 13:04 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
SaleCommon Stock | 5,902 | $169.80 | $1,002,171.99 |
DisclosureSEC source: 0001127602-19-027809 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,097 F1 · price: The price of $169.8021 per share represents a weighted average of sales prices ranging from $169.7868 to $169.8445 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| August 07, 2019 Filed Feb 6, 2020 19:55 UTC |
Williams R SandersDirector
|
GiftCommon Stock | 1,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003964 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,095 Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 15:40 UTC |
Williams R SandersDirector
|
SaleCommon Stock | 500 | $162.91 | $81,455.00 |
DisclosureSEC source: 0001127602-19-026206 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,886 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 13:03 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
SaleCommon Stock | 5,563 | $176.75 | $983,260.25 |
DisclosureSEC source: 0001127602-19-024269 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,059 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 13:02 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
SaleCommon Stock | 2,328 | $176.75 | $411,474.00 |
DisclosureSEC source: 0001127602-19-024268 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,328.2468 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:26 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionNon-qualified Stock Options · Derivative | 3,100 | $0.00 Strike: $77.19 | $0.00 |
DisclosureSEC source: 0001127602-19-022529 · form4.xml · derivative · entry 3 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,100 shares Expires 2020-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Director stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2008 Stock Incentive Plan. F3 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:26 UTC |
ANDERSON KERRII BDirector
|
SaleCommon Stock | 3,100 | $170.00 | $527,000.00 |
DisclosureSEC source: 0001127602-19-022529 · form4.xml · nonDerivative · entry 2 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,133 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.